US FDA Approves Takeda’s Livtencity Drug For Treating Post-Transplant Cytomegalovirus (CMV) Infection

Takeda Pharmaceutical has announced that, the US FDA has given the approval to the Livtencity (maribavir) drug for the purpose of treating the adults and the pediatric patients suffering from the post-transplant CMV infection that is having a refractory to the treatment with ganciclovir, cidofovir, foscarnet or valganciclovir.

More than double the proportion of the adult transplant patients with the resistant CMV has achieved confirmed CMV level of DNA at the week eight, and the primary end point of the study with Livtencity as compared to those people, who have been treated with the conventional antiviral therapies.

The company said, the drug Livtencity has been the second new molecular entity of Takeda for receiving the approval from the US FDA in the financial year 2021. Ramona Sequeira, president of Global Portfolio Commercialisation and US Business Unit at Takeda Pharmaceutical said, this announcement has been redefining the management of the post-transplant CMV along with the approval of the first and only treatment for the patients of transplants with the CMV that has been refractory with or without any resistance, which has been a significantly underserved.

Ramona Sequeira also said, the patients that are undergoing the transplants are having a healthcare journey, which is very complex and lengthy, along with the approval of this treatment, they are very proud for offering the people a new oral antiviral drug or medicine for their fight against the CMV infection and disease. She added that, they are very grateful for the contributions made from the patients and the clinicians in their clinical trials.